Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
9 April 2020Americas

Kite must pay $1.2bn for infringing CAR-T patent

A California federal judge has issued a final award of $1.2 billion in damages to  Bristol-Myers Squibb subsidiary  Juno Therapeutics in its patent infringement dispute with  Gilead’s Kite Pharma.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Kite says $1.2 billion Juno award will ‘kill innovation’
2 September 2020   Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
Biotechnology
Gilead fails to overturn $752m BMS patent verdict
2 April 2020   A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Kite says $1.2 billion Juno award will ‘kill innovation’
2 September 2020   Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
Biotechnology
Gilead fails to overturn $752m BMS patent verdict
2 April 2020   A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.

More on this story

Americas
Kite says $1.2 billion Juno award will ‘kill innovation’
2 September 2020   Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
Biotechnology
Gilead fails to overturn $752m BMS patent verdict
2 April 2020   A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB